I-MAB (NASDAQ: IMAB)
$1.63
-0.0050 ( -0.31% ) 375.2K
I-Mab Biopharma is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Market Data
Open
$1.63
Previous close
$1.63
Volume
375.2K
Market cap
$131.84M
Day range
$1.57 - $1.69
52 week range
$1.16 - $3.17
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 3 | Jul 15, 2024 |
6-k | Quarterly Reports | 29 | Jun 06, 2024 |
6-k | Quarterly Reports | 4 | Jun 05, 2024 |
6-k | Quarterly Reports | 3 | May 23, 2024 |
20-f | Annual reports | 129 | Apr 30, 2024 |
6-k | Quarterly Reports | 1 | Apr 15, 2024 |
6-k | Quarterly Reports | 2 | Apr 02, 2024 |
6-k | Quarterly Reports | 1 | Apr 01, 2024 |
6-k | Quarterly Reports | 2 | Mar 15, 2024 |
6-k | Quarterly Reports | 6 | Feb 07, 2024 |